MXCT
What one share of MaxCyte holds
Services – Commercial Physical and Biological Research
We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics including cell and gene therapies and to support innovative cell-based research and development.
MaxCyte’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.29 |
|---|---|
| Profit | −$0.33 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.22 |
| Cash and investments | $0.14 |
| Book value | $1.50 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.38 | −$0.23 | $0.02 | −$0.18 | — | $0.24 |
| 2020 | $0.38 | −$0.17 | $0.03 | −$0.16 | — | $0.43 |
| 2021 | $0.37 | −$0.21 | $0.04 | −$0.16 | — | $2.60 |
| 2022 | $0.44 | −$0.23 | $0.18 | −$0.33 | — | $2.48 |
| 2023 | $0.40 | −$0.37 | $0.04 | −$0.25 | — | $2.23 |
| 2024 | $0.37 | −$0.39 | $0.02 | −$0.28 | — | $1.95 |
| 2025 | $0.31 | −$0.42 | $0.02 | −$0.34 | — | $1.61 |